Impact of Molecular Tumor Board on Clinical Outcomes in Patients with Refractory Solid Tumor: a Real-World Study
MTB improves oncologic prognosis in patients with refractory solid tumor, and matching MTB-recommended therapy is an independent factor for OS and PFS.
Authors
- Xiao-Peng Duan (ORCID: https://orcid.org/0000-0002-2421-1756)
- Li Sun (ORCID: https://orcid.org/0000-0001-6141-562X)
- Bao‐Dong Qin
- Xiao‐Dong Jiao (ORCID: https://orcid.org/0000-0002-9663-8548)
- Yan Ling (ORCID: https://orcid.org/0009-0005-4057-8987)
- Xue Zhong
- Ke Liu (ORCID: https://orcid.org/0009-0002-0594-4484)
- Bing Li (ORCID: https://orcid.org/0000-0001-7127-1447)
- Shiqi Chen (ORCID: https://orcid.org/0000-0001-7420-0142)
- Ying Wu (ORCID: https://orcid.org/0000-0003-4510-5984)
- Yuan‐Sheng Zang (ORCID: https://orcid.org/0000-0002-9488-7305)
- Juan Ding (ORCID: https://orcid.org/0000-0001-9598-381X)
- Zhan Wang (ORCID: https://orcid.org/0009-0000-6968-7638)
- Wenxing Qin
- Dong-Min Shi
Institutions
- Shanghai Changzheng Hospital (CN)
- Burning Rock Biotech (China) (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf196
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Science and Technology Commission of Shanghai Municipality